Skip to content
  • Categories
  • Recent
  • Tags
  • Popular
  • Users
  • Groups
Skins
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Collapse
Brand Logo

Forum

U

uarabi90

@uarabi90
Manufacturer

Forum Update: Supporting Community-Led Discussion

The forum was created as a space for shared learning and peer support, and as the community grows, we want to lean more fully into that purpose.

Going forward, PAAB will be taking a more listening-first role in forum discussions. Rather than responding immediately to every question, we’ll be encouraging members to engage with one another, share experiences, and help build collective understanding. PAAB will continue to monitor conversations and will step in to:

  • Correct any misunderstandings
  • Provide guidance when questions remain unanswered after a few days
  • Support discussions where official clarification is needed

Our goal is to foster a collaborative, trusted community where knowledge is shared and strengthened by everyone’s contributions.

Thank you for being part of the conversation.

About
Posts
1
Topics
1
Shares
0
Groups
1
Followers
1
Following
0

Posts

Recent Best Controversial

  • Disease State Clinical Reprint
    U uarabi90

    Hello. I had a very specific question regarding journal reprints. With respect to clinical reprints that are more focused on disease state and/or are meant to be practice defining documents (clinical resource documents, guidelines); can they be shared in a promotional way by sales reps (ie with accompanying word of mouth, in proactive manner etc).
    I understand that in a previous question, it was clarified that clinical reprints must abide by PAAB codes sections 2,3,4,5. However, in section 3.1.1 it states that Review articles, pooled data,
    meta-analysis, post-hoc analysis, and observational studies are
    generally regarded as not being evidence to support claims in drug
    advertising. However, in the context of review articles discussing disease state or practice defining documents, does this point still apply? as the reprint is meant to raise awareness on the disease state and clinical practice for managing the patient population?

    thanks in advance for your consideration and support.

    CME, educational material, Reprints, reports, textbooks, independently created content
  • Login

  • Don't have an account? Register

  • Login or register to search.
  • First post
    Last post
0
  • Categories
  • Recent
  • Tags
  • Popular
  • Users
  • Groups